

# Privileged Structures in Drug Discovery

Medicinal Chemistry and Synthesis

*Larry Yet .*

*Department of Chemistry,  
University of South Alabama  
Mobile, AL, USA*

**WILEY**

## Contents

|          |  |           |
|----------|--|-----------|
| <b>1</b> | <b>Introduction</b>  | <b>1</b>  |
| 1.1      | The Original Definition of Privileged Structures   | 1         |
| 1.2      | The Role of Privileged Structures in the Drug Discovery Process  | 1         |
| 1.3      | The Loose Definitions of "Privileged Structures"   | 2         |
| 1.4      | Synthesis and Biological Activities of Carbocyclic and Heterocyclic Privileged Structures                          | 2         |
| 1.4.1    | Synthesis and Biological Activities of Three- and Four-Membered Ring Privileged Structures                         | 2         |
| 1.4.2    | Synthesis and Biological Activities of Five-Membered Ring Privileged Structures                                    | 2         |
| 1.4.3    | Synthesis and Biological Activities of Six-Membered Ring Privileged Structures                                     | 4         |
| 1.4.4    | Synthesis and Biological Activities of Bicyclic 5/5 and 6/5 Ring Privileged Structures                             | 4         |
| 1.4.5    | Synthesis and Biological Activities of Bicyclic 6/6 and 6/7 Ring Privileged Structures                             | 4         |
| 1.4.6    | Synthesis and Biological Activities of Tricyclic and Tetracyclic Ring Privileged Structures                        | 4         |
| 1.5      | Combinatorial Libraries of "Privileged Structures"   | 4         |
| 1.6      | Scope of this Monograph  | 9         |
|          | References   | 10        |
| <br>     |  |           |
| <b>2</b> | <b>Benzodiazepines</b>   | <b>15</b> |
| 2.1      | Introduction   | 15        |
| 2.2      | Marketed BDZ Drugs   | 15        |
| 2.2.1    | 1,4-Benzodiazepine Marketed Drugs  | 15        |
| 2.2.2    | 1,5-Benzodiazepine Marketed Drugs  | 16        |
| 2.2.3    | Linearly Fused BDZ Marketed Drugs  | 16        |
| 2.2.4    | Angularly Fused-1,4-Benzodiazepine Marketed Drugs  | 17        |
| 2.3      | Medicinal Chemistry Case Studies   | 17        |
| 2.3.1    | Cardiovascular Applications  | 17        |
| 2.3.2    | Central Nervous System Applications  | 19        |
| 2.3.3    | Gastrointestinal Applications  | 23        |
| 2.3.4    | Infectious Diseases Applications   | 24        |
| 2.3.5    | Inflammation Applications  | 25        |
| 2.3.6    | Metabolic Diseases Applications  | 27        |
| 2.3.7    | Oncology Applications  | 28        |
| 2.4      | Synthesis of BDZs  | 30        |
| 2.4.1    | Condensation of <i>o</i> -Phenylenediamines to 1,5-Benzodiazepines   | 31        |
| 2.4.1.1  | Condensation of <i>o</i> -Phenylenediamines with Ketones   | 31        |
| 2.4.1.2  | Condensation of <i>o</i> -Phenylenediamines with $\alpha,\beta$ -Unsaturated Ketones                               | 33        |
| 2.4.1.3  | Condensation of <i>o</i> -Phenylenediamines with Alkynes   | 34        |
| 2.4.2    | Reductive Condensation of $\alpha$ -Substituted Nitrobenzenes with Ketones and $\alpha,\beta$ -Unsaturated Ketones | 35        |
| 2.4.3    | Intramolecular Cyclizations to 1,4-Benzodiazepines   | 35        |
| 2.4.3.1  | Intramolecular Cyclizations—Path A   | 36        |
| 2.4.3.2  | Intramolecular Cyclizations—Path B   | 37        |
| 2.4.3.3  | Intramolecular Cyclizations—Path C   | 39        |

|          |  |           |
|----------|--|-----------|
| 2.4.3.4  | Intramolecular Cyclizations—Path D                           | 40        |
| 2.4.3.5  | Intramolecular Cyclizations—Path E                           | 42        |
| 2.4.3.6  | Intramolecular Cyclizations—Path F                           | 42        |
| 2.4.3.7  | Intramolecular Cyclizations—Path G                           | 42        |
| 2.4.3.8  | Intramolecular Cyclizations—Path H                           | 42        |
| 2.4.4    | Ugi Multicomponent Synthesis                                 | 42        |
| 2.4.5    | Elaboration of 1,4-Benzodiazepines                           | 44        |
| 2.4.6    | Pyrrolo[2,1- <i>c</i> ]benzodiazepines                       | 45        |
| 2.4.7    | Fused BDZ Ring Systems                                       | 45        |
| 2.4.8    | Solid-Phase Synthesis of BDZs                                | 47        |
|          | References   | 47        |
| <b>3</b> | <b>1,4-Dihydropyridines</b>                                  | <b>59</b> |
| 3.1      | Introduction   | 59        |
| 3.2      | Marketed 1,4-Dihydropyridine Drugs                           | 59        |
| 3.3      | Medicinal Chemistry Case Studies                             | 59        |
| 3.3.1    | Cardiovascular Applications                                  | 59        |
| 3.3.2    | Central Nervous System Applications                          | 61        |
| 3.3.3    | Infectious Diseases Applications                             | 62        |
| 3.3.4    | Inflammation Applications                                    | 63        |
| 3.3.5    | Men's and Women's Health Issues Applications                 | 64        |
| 3.3.6    | Metabolic Diseases Applications                              | 65        |
| 3.3.7    | Oncology Applications  | 65        |
| 3.4      | Synthesis of 1,4-Dihydropyridines                            | 66        |
| 3.4.1    | Classical Hantzsch Synthesis                                 | 66        |
| 3.4.2    | Modified Hantzsch Conditions                                 | 66        |
| 3.4.3    | 1,4-Disubstituted-1,4-Dihydropyridines                       | 69        |
| 3.4.4    | Organometallic Additions to Pyridinium Salts                 | 69        |
| 3.4.5    | From Imines and Enamino Compounds                            | 71        |
| 3.4.6    | Multicomponent Synthesis                                     | 72        |
| 3.4.6.1  | Three-Component Synthesis of 1,4-Dihydropyridines            | 72        |
| 3.4.6.2  | Four-Component Synthesis of 1,4-Dihydropyridines             | 74        |
| 3.4.7    | Organocatalytic Synthesis of 1,4-Dihydropyridines            | 74        |
| 3.4.8    | Miscellaneous Preparations                                   | 75        |
| 3.4.9    | Elaboration of 1,4-Dihydropyridines                          | 76        |
|          | References   | 77        |
| <b>4</b> | <b>Biaryls</b>   | <b>83</b> |
| 4.1      | Introduction   | 83        |
| 4.2      | Marketed Biaryl Drugs  | 83        |
| 4.3      | Medicinal Chemistry Case Studies                             | 87        |
| 4.3.1    | Cardiovascular Applications                                  | 87        |
| 4.3.2    | Central Nervous System Applications                          | 89        |
| 4.3.3    | Infectious Diseases Applications                             | 95        |
| 4.3.4    | Inflammation Applications                                    | 98        |
| 4.3.5    | Men's and Women's Health Issues Applications                 | 102       |
| 4.3.6    | Metabolic Diseases Applications                              | 103       |
| 4.3.7    | Oncology Applications  | 109       |
| 4.4      | Synthesis of Biaryls   | 114       |
| 4.4.1    | Transition Metal-Catalyzed Cross-Coupling Synthesis          | 114       |
| 4.4.1.1  | Suzuki–Miyaura Cross-Coupling Reactions with Boronic Acids   | 114       |
| 4.4.1.2  | Suzuki–Miyaura Cross-Coupling Reactions with Boronate Esters | 114       |
| 4.4.1.3  | Metal-Catalyzed Homocoupling Reactions                       | 121       |

- 4.4.1.4 Uhlmann Coupling Reactions 122
- 4.4.1.5 Kumada–Tamao–Corriu Cross-Coupling Reactions 123
- 4.4.1.6 Negishi Cross-Coupling Reactions 124
- 4.4.1.7 Hiyama Cross-Coupling Reactions 124
- 4.4.1.8 Stille Cross-Coupling Reactions 125
- 4.4.1.9 Miscellaneous Cross-Coupling Reactions 126
- 4.4.1.10 Metal-Catalyzed Functional Group Removal Cross-Coupling Reaction 127
- 4.4.2 C–H Functionalization Reactions 127
  - 4.4.2.1 Oxidative Coupling Reactions 127
  - 4.4.2.2 Direct C–H Arylations 127
  - 4.4.2.3 C–H Functionalization with Directing Groups 127
- 4.4.3 Cycloaddition Reactions 132
  - 4.4.3.1 [3+3] Cycloaddition Reactions 132
  - 4.4.3.2 [4+2] Cycloaddition Reactions 132
  - 4.4.3.3 [2+2+2] Cycloaddition Reactions 133
  - 4.4.3.4 Tandem Cycloaddition Reactions 133
- 4.4.4 Biaryl Phenol Syntheses 133
- 4.4.5 Miscellaneous Syntheses 134
- References 135
  
- 5 4-(Hetero)Arylpiperidines 155**
  - 5.1 Introduction 155
  - 5.2 Marketed 4-(Hetero)Arylpiperidine Drugs 155
  - 5.3 Medicinal Chemistry Case Studies 159
    - 5.3.1 Cardiovascular Applications 159
    - 5.3.2 Central Nervous System Applications 159
    - 5.3.3 Infectious Diseases Applications 168
    - 5.3.4 Inflammation Applications 169
    - 5.3.5 Men's and Women's Health Applications 174
    - 5.3.6 Metabolic Diseases Applications 175
    - 5.3.7 Oncology Applications 177
  - 5.4 Synthesis of 4-(Hetero)Arylpiperidines 179
    - 5.4.1 Preparation from 4-Piperidinones 179
    - 5.4.2 Preparation from 4-Prefunctionalized-3-alkenylpiperidines 180
    - 5.4.3 Preparation from Negishi Cross-Coupling of 3-Zincated Piperidines 180
    - 5.4.4 Preparation from 4-Functionalized Piperidines 181
    - 5.4.5 Conjugated Addition to Unsaturated Piperidines 181
    - 5.4.6 Miscellaneous Syntheses 183
  - References 185
  
- 6 Spiropiperidines 194**
  - 6.1 Introduction 194
  - 6.2 Marketed Spiropiperidine Drugs 194
  - 6.3 Medicinal Chemistry Case Studies 195
    - 6.3.1 Cardiovascular Applications 195
    - 6.3.2 Central Nervous System Applications 197
    - 6.3.3 Infectious Diseases Applications 203
    - 6.3.4 Inflammation Applications 205
    - 6.3.5 Men's and Women's Health Applications 210
    - 6.3.6 Metabolic Diseases Applications 211
    - 6.3.7 Oncology Applications 216
  - 6.4 Synthesis of Spiropiperidines 218
    - 6.4.1 Quinolinylospiroperidines 218

- 6.4.2 Azaspiro[5.5]alkane Systems 218
  - 6.4.3 Diazaspiro[5.5]alkane Derivatives 221
  - 6.4.4 1,4-Benzodioxinylspiropiperidines 222
  - 6.4.5 Spirobenzooxazinylspiropiperidines 223
  - 6.4.6 (Iso)Quinolinylnspiropiperidines 223
  - 6.4.7 Indenospiropiperidines 225
  - 6.4.8 Indolin(on)ylspiropiperidines 225
  - 6.4.9 Cyclohexadienonylspiropiperidines 226
  - 6.4.10 Cyclopenta[*b*]pyrrolospiropiperidines 226
  - 6.4.11 Chromanylspiropiperidines 226
  - 6.4.12 (Iso)Benzofuran(on)ylspiropiperidines 227
  - 6.4.13 Indenospiropiperidines 227
  - References 228
- 
- 7 2-Aminopyrimidines 237**
  - 7.1 Introduction 237
  - 7.2 Marketed 2-Aminopyrimidine Drugs 237
  - 7.3 Medicinal Chemistry Case Studies 239
    - 7.3.1 Cardiovascular Applications 239
    - 7.3.2 Central Nervous System Applications 241
    - 7.3.3 Infectious Diseases Applications 245
    - 7.3.4 Inflammation Applications 248
    - 7.3.5 Metabolic Diseases Applications 254
    - 7.3.6 Miscellaneous Applications 255
    - 7.3.7 Oncology Applications 256
  - 7.4 Synthesis of 2-Aminopyrimidines 267
    - 7.4.1 Aminations with 2-Halo or 2,4-Dihalopyrimidines 267
    - 7.4.2 Cross-Coupling Reactions with 2-Aminopyrimidines 270
    - 7.4.3 Aminations with 2-Sulfonylpyrimidines 270
    - 7.4.4 Cyclizations with Guanidines 272
  - References 272
- 
- 8 2-Aminothiazoles 284**
  - 8.1 Introduction 284
  - 8.2 Marketed 2-Aminothiazole Drugs 284
  - 8.3 Medicinal Chemistry Case Studies 286
    - 8.3.1 Cardiovascular Diseases Applications 286
    - 8.3.2 Central Nervous System Applications 288
    - 8.3.3 Infectious Diseases Applications 292
    - 8.3.4 Inflammation Applications 296
    - 8.3.5 Metabolic Diseases Applications 299
    - 8.3.6 Oncology Applications 301
    - 8.3.7 Miscellaneous Applications 305
  - 8.4 Synthesis of 2-Aminothiazoles 306
    - 8.4.1 Hantzsch Synthesis from  $\alpha$ -Functionalized Ketones and Thioureas 306
    - 8.4.2 Hantzsch Synthesis from Ketones and Thioureas 306
    - 8.4.3 Synthesis from  $\alpha$ -Haloketones and Thiocyanates 308
    - 8.4.4 Synthesis from Vinyl Azides and Thiocyanates 308
    - 8.4.5 Synthesis from Amidines and Thiocyanates 309
    - 8.4.6 Synthesis from Alkenyl and Alkynyl Compounds with Thiocyanates or Thioureas 309
    - 8.4.7 Miscellaneous Syntheses 309
    - 8.4.8 Elaboration of 2-Aminothiazoles 311
  - References 311

|           |   |            |
|-----------|---|------------|
| <b>9</b>  | <b>2-(Hetero)Arylindoles</b>  | <b>321</b> |
| 9.1       | Introduction  | 321        |
| 9.2       | Marketed 2-Arylindole Drugs   | 321        |
| 9.3       | Medicinal Chemistry Case Studies  | 321        |
| 9.3.1     | Cardiovascular Applications   | 321        |
| 9.3.2     | Central Nervous System Applications   | 322        |
| 9.3.3     | Infectious Diseases Applications  | 323        |
| 9.3.4     | Inflammation Applications   | 325        |
| 9.3.5     | Men's and Women's Health Applications   | 326        |
| 9.3.6     | Metabolic Diseases Applications   | 328        |
| 9.3.7     | Miscellaneous Applications  | 328        |
| 9.3.8     | Oncology Applications   | 328        |
| 9.4       | Synthesis of 2-(Hetero)Arylindoles  | 332        |
| 9.4.1     | Functionalization to the Preformed Indole System  | 332        |
| 9.4.1.1   | 2-Functionalized Metallated Indoles with Aryl Halides (Strategy 1)                          | 332        |
| 9.4.1.2   | 2-Halogenated or 2-Triflated Indoles with Functionalized Arenes (Strategy 1)                | 332        |
| 9.4.1.3   | Direct Arylation of Indole with Functionalized Arenes (Strategy 2)                          | 334        |
| 9.4.1.4   | Direct Oxidative Coupling of Indoles with (Hetero)Arenes (Strategy 3)                       | 334        |
| 9.4.2     | Fischer Indole Synthesis  | 334        |
| 9.4.3     | Bischler–Mohlau Indole Synthesis  | 334        |
| 9.4.4     | Metal-Catalyzed Approach with Alkynes   | 334        |
| 9.4.4.1   | Intramolecular Cyclizations of <i>o</i> -Alkynylanilines (Strategy A)                       | 336        |
| 9.4.4.2   | Intramolecular Cyclizations of <i>o</i> -Alkynylanilines with Other Groups (Strategy B)     | 336        |
| 9.4.4.3   | Intramolecular Cyclizations of <i>o</i> -Haloanilines with Alkynes (Strategy C)             | 337        |
| 9.4.4.4   | Intramolecular Cyclizations of <i>o</i> -Alkynylhaloarenes with Primary Amines (Strategy D) | 340        |
| 9.4.4.5   | Miscellaneous Transition Metal-Catalyzed Reactions  | 340        |
| 9.4.4.6   | Reductive Cyclizations of <i>o</i> -Nitroalkynylarenes                                      | 342        |
| 9.4.5     | Intramolecular Reductive Cyclizations of <i>o</i> -Nitro (or Azido)alkenylarenes            | 342        |
| 9.4.6     | Cyclizations of Arylamido and Arylimine Precursors  | 343        |
| 9.4.7     | Cyclizations of <i>o</i> -Vinylaminoarenes  | 344        |
| 9.4.8     | Cyclizations with <i>N</i> -Arylenamines or <i>N</i> -Arylenaminones                        | 344        |
| 9.4.9     | Multicomponent Synthesis  | 345        |
| 9.4.10    | Radical Cyclization Reactions   | 346        |
| 9.4.11    | Miscellaneous Cyclizations with <i>o</i> -Substituted Anilines                              | 346        |
|           | References  | 348        |
| <b>10</b> | <b>Tetrahydroisoquinolines</b>  | <b>356</b> |
| 10.1      | Introduction  | 356        |
| 10.2      | Marketed THIQ Drugs   | 356        |
| 10.3      | Medicinal Chemistry Case Studies  | 357        |
| 10.3.1    | Cardiovascular Applications   | 357        |
| 10.3.2    | Central Nervous System Applications   | 359        |
| 10.3.3    | Infectious Diseases Applications  | 365        |
| 10.3.4    | Inflammation Applications   | 366        |
| 10.3.5    | Men's and Women's Health Applications   | 369        |
| 10.3.6    | Metabolic Diseases Applications   | 369        |
| 10.3.7    | Miscellaneous Applications  | 370        |
| 10.3.8    | Oncology Applications   | 372        |
| 10.4      | Synthesis of THIQs  | 376        |
| 10.4.1    | Pictet–Spengler Reactions   | 376        |
| 10.4.1.1  | Classical Pictet–Spengler Reactions   | 376        |
| 10.4.1.2  | Pictet–Spengler Reactions with Masked Carbonyl Compounds                                    | 377        |
| 10.4.1.3  | Modified Pictet–Spengler Reactions  | 377        |
| 10.4.1.4  | Pictet–Spengler-Type Reactions  | 377        |

|           |   |            |
|-----------|---|------------|
| 10.4.1.5  | Pictet–Spengler Synthesis of Tic  | 378        |
| 10.4.2    | Transition Metal-Catalyzed Reactions  | 379        |
| 10.4.2.1  | Intramolecular $\alpha$ -Arylation Reactions  | 379        |
| 10.4.2.2  | Intramolecular Cyclizations of <i>N</i> -Propargylbenzylamines  | 379        |
| 10.4.2.3  | Intramolecular Heck Cyclizations  | 379        |
| 10.4.2.4  | Intramolecular Nucleophilic Additions   | 379        |
| 10.4.2.5  | One-Pot Multistep Metal-Catalyzed Cyclization Reactions   | 380        |
| 10.4.3    | Multicomponent Synthesis of THIQs   | 382        |
| 10.4.4    | Synthesis of 3-Aryltetrahydroisoquinolines  | 382        |
| 10.4.5    | Synthesis of 4-Aryltetrahydroisoquinolines  | 383        |
| 10.4.6    | Miscellaneous Intramolecular Cyclizations   | 386        |
| 10.4.7    | Asymmetric Reduction of 1-Substituted-3,4-Dihydroisoquinolines  | 387        |
| 10.4.7.1  | Iridium-Catalyzed Hydrogenations of Dihydroisoquinolines, Isoquinoline Salts, and Isoquinolines                   | 388        |
| 10.4.7.2  | Ruthenium- and Rhodium-Catalyzed Reductions of Dihydroisoquinolines   | 389        |
| 10.4.7.3  | Asymmetric Additions to Dihydroisoquinolines, Dihydroisoquinoline Salts, and Dihydroisoquinoline <i>N</i> -Oxides | 389        |
| 10.4.7.4  | Asymmetric Intramolecular Cyclizations  | 391        |
| 10.4.7.5  | Asymmetric Intramolecular Cyclizations with Chiral Sulfoxides   | 391        |
| 10.4.7.6  | Miscellaneous Asymmetric Preparations   | 392        |
| 10.4.8    | Arylations of THIQs   | 393        |
| 10.4.9    | C–H Functionalization of THIQs  | 395        |
| 10.4.9.1  | Direct C-1 (Hetero)Arylations of THIQs  | 395        |
| 10.4.9.2  | Oxidative C-1 CDC Reactions   | 395        |
| 10.4.9.3  | Oxidative C-1 CDC with $\beta$ -Ketoesters  | 396        |
| 10.4.9.4  | Oxidative C-1 CDC with Ketones  | 397        |
| 10.4.9.5  | Oxidative C-1 CDC with Indoles  | 397        |
| 10.4.9.6  | Oxidative C-1 CDC with Aliphatic Nitro Compounds  | 398        |
| 10.4.9.7  | Oxidative C-1 CDC with Alkynes  | 399        |
| 10.4.9.8  | Oxidative C-1 CDC with Alkenes  | 399        |
| 10.4.9.9  | Oxidative C-1 Cross-Dehydrogenative Phosphonations  | 400        |
| 10.4.9.10 | Miscellaneous Oxidative C-1 CDC Reactions   | 400        |
|           | References  | 401        |
| 11        | <b>2,2-Dimethylbenzopyrans</b>  | <b>414</b> |
| 11.1      | Introduction  | 414        |
| 11.2      | Marketed 2,2-Dimethylopyran Drugs   | 414        |
| 11.3      | Medicinal Chemistry Case Studies  | 415        |
| 11.3.1    | Cardiovascular Applications   | 415        |
| 11.3.2    | Central Nervous System Applications   | 416        |
| 11.3.3    | Infectious Diseases Applications  | 418        |
| 11.3.4    | Inflammation Applications   | 419        |
| 11.3.5    | Metabolic Diseases Applications   | 419        |
| 11.3.6    | Oncology Applications   | 419        |
| 11.3.7    | Cannabinoid Receptors   | 421        |
| 11.4      | Synthesis of 2,2-Dimethylbenzopyrans  | 423        |
| 11.4.1    | Annulations of Phenol Derivatives with Unsaturated Systems  | 423        |
| 11.4.1.1  | Annulations of Phenol Derivatives with Simple Alkenes   | 423        |
| 11.4.1.2  | Annulations of Phenol Derivatives with $\alpha,\beta$ -Unsaturated Systems  | 424        |
| 11.4.1.3  | Annulations of Phenol Derivatives with Nitroalkenes   | 424        |
| 11.4.1.4  | Annulations of Phenol Derivatives with Allylic Alcohols   | 424        |
| 11.4.1.5  | Annulations of Phenol Derivatives with Propargyl Alcohols   | 425        |
| 11.4.2    | Replacement of the Methyl Group of 2,2-Dimethylbenzopyrans  | 425        |

- 11.4.3 Functionalization of 2,2,-Dimethylbenzopyrans 426
- 11.4.4 Fused 2,2-Dimethylbenzopyran Ring Systems 428
- 11.4.5 Solid-Phase Synthesis of 2,2-Dimethylbenzopyrans 428
- References 429
  
- 12 Hydroxamates 435**
- 12.1 Introduction 435
- 12.2 Marketed Hydroxame Drugs 435
- 12.3 Medicinal Chemistry Case Studies 436
- 12.3.1 Central Nervous System Applications 436
- 12.3.2 Infectious Diseases Applications 436
- 12.3.3 Inflammation Applications 439
- 12.3.4 Men's and Women's Health Applications 452
- 12.3.5 Metabolic Diseases Applications 453
- 12.3.6 Oncology Applications 453
- 12.4 Synthesis of Hydroxamates 466
- 12.4.1 Synthesis of Hydroxamates from Carboxylic Acids 466
- 12.4.2 Synthesis of Hydroxamates from Carboxylic Acid Derivatives 466
- 12.4.2.1 Synthesis of Hydroxamates from Esters 466
- 12.4.2.2 Synthesis of Hydroxamates from Acid Chlorides 468
- 12.4.2.3 Synthesis of Hydroxamates from Oxazolidinones 468
- 12.4.3 Miscellaneous Syntheses of Hydroxamates 469
- 12.4.4 Solid-Phase Synthesis of Hydroxamates 469
- References 470
  
- 13 Bicyclic Pyridines Containing Ring-Junction Nitrogen 481**
- 13.1 Introduction 481
- 13.2 Marketed Bicyclic Ring-Junction Pyridine Drugs 481
- 13.3 Medicinal Chemistry Case Studies 482
- 13.3.1 Cardiovascular Applications 482
- 13.3.2 Central Nervous System Applications 483
- 13.3.3 Gastrointestinal Applications 487
- 13.3.4 Infectious Diseases Applications 488
- 13.3.5 Inflammation Applications 491
- 13.3.6 Metabolic Diseases Applications 493
- 13.3.7 Miscellaneous Applications 494
- 13.3.8 Oncology Applications 494
- 13.4 Synthesis of Pyrazolo[1,5-*a*]pyridines 498
- 13.4.1 [3+2] Dipolar Cycloadditions 498
- 13.4.2 Intramolecular Cyclizations 499
- 13.4.3 From *N*-Aminopyridinium Ylides 500
- 13.4.4 From 2-Substituted Pyridines 500
- 13.4.5 Thermal and Radical Cyclizations 500
- 13.5 Synthesis of Imidazo[1,5-*a*]pyridines 501
- 13.5.1 From 2-Methylaminopyridines 501
- 13.5.2 From 2-Methylaminopyridine Amides 502
- 13.5.3 From 2-Methylaminopyridine Thioamides or Thioureas 503
- 13.5.4 From Pyridine-2-Carbaldehydes (Picolinaldehydes) 503
- 13.5.5 From 2-Cyanopyridines 503
- 13.5.6 From Pyridine-2-Esters 504
- 13.5.7 From Di-2-Pyridyl Ketones 504
- 13.5.8 From Pyridotriazoles 504
- 13.5.9 Miscellaneous Syntheses 504



|           |   |            |
|-----------|---|------------|
| 13.5.10   | Chemical Elaborations of Imidazo[1,5- <i>a</i> ]pyridines                                 | 505        |
| 13.6      | Synthesis of Imidazo[1,2- <i>a</i> ]pyridines   | 507        |
| 13.6.1    | Ugi Three-Component Reactions   | 507        |
| 13.6.1.1  | Classical Ugi Three-Component Reactions of 2-Aminopyridines, Aldehydes, and (Iso)Nitriles | 507        |
| 13.6.1.2  | Modified Ugi Three-Component Reactions  | 507        |
| 13.6.2    | From 2-Aminopyridines and Carbonyl Compounds  | 509        |
| 13.6.2.1  | From 2-Aminopyridines and Methyl Ketones  | 509        |
| 13.6.2.2  | From 2-Aminopyridines and $\beta$ -Ketoesters   | 509        |
| 13.6.2.3  | From 2-Aminopyridines and Miscellaneous Ketones   | 510        |
| 13.6.2.4  | From Pyridines and 2-Aminopyridines with $\alpha$ -Haloketones or $\alpha$ -Haloaldehydes | 511        |
| 13.6.3    | From 2-Aminopyridines and Alkynes   | 512        |
| 13.6.3.1  | From 2-Aminopyridines and Alkynes   | 512        |
| 13.6.3.2  | From 2-Aminopyridines, Alkynes, and Aldehydes   | 513        |
| 13.6.4    | From 2-Aminopyridines and $\alpha,\beta$ -Unsaturated Systems                             | 513        |
| 13.6.5    | From 2-Aminopyridines and Nitroolefins  | 515        |
| 13.6.6    | Cyclizations from 2-Aminopropargylpyridines   | 515        |
| 13.6.7    | Cyclizations from Pyridyl Enamines(ones)  | 517        |
| 13.6.8    | From Other Heterocycles   | 517        |
| 13.6.9    | Miscellaneous Syntheses   | 518        |
| 13.6.10   | Chemical Elaboration of Imidazo[1,2- <i>a</i> ]pyridines                                  | 520        |
| 13.6.10.1 | Cross-Coupling Reactions of Pre-functionalized Imidazo[1,2- <i>a</i> ]pyridines           | 520        |
| 13.6.10.2 | C–H Functionalization of Imidazo[1,2- <i>a</i> ]pyridines                                 | 521        |
| 13.6.11   | Fused Imidazo[1,2- <i>a</i> ]pyridine Ring Systems  | 523        |
|           | References  | 525        |
|           | <b>Index</b>  | <b>536</b> |